公司資料
Tiziana Life Sciences 股價、新聞與催化劑
- 股票代碼:
- TLSA
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United Kingdom and trades in the U
股票表現
1.15 USD (+1.32%)
收盤價
最後更新: 2026年8月17日
173M USD
市值
股價為何變動
As of Aug 17, 2026, TLSA closed up 1.32% at $1.15. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Tiziana Life Sciences is a biotechnology company focused on immune modulation and respiratory or inflammatory disease applications. Its story centers on using biologic or cellular approaches to influence difficult disease pathways.
所在地與產業分類
Tiziana is headquartered in the United Kingdom and trades in the U.S. market. It sits in small-cap biotechnology.
商業模式特徵
The company depends on translational progress, clinical validation, and strategic focus across a narrow pipeline. Investors usually watch early data and whether the platform can sharpen its therapeutic thesis.
生技產業定位
Tiziana occupies a niche immune-modulation position within biotech. It is a catalyst-driven small-cap name where scientific proof matters more than commercial scale.
未來催化劑
- Tiziana’s catalysts are foralumab and the neuro / autoimmune programs, with any update that clarifies whether the platform can still progress. The market will want a cleaner clinical path.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。